Cytarabine combined with an anthracycline or an anthracenedione represents the usual
intensive induction therapy for the treatment of AML. However, this protocol induces severe …

The selective targeting of cytotoxic compounds is one of the major challenges in cancer
chemotherapy. Most anticancer drugs lack any intrinsic selectivity, causing severe side …

Up-regulation of folate receptor (FR) type-β in acute myelogenous leukemia (AML) by all-
trans retinoic acid (ATRA) and its restricted normal tissue distribution makes it a potential …

Strategic modalities of drug delivery have the potential to greatly improve the therapeutic
efficacy of available drugs in acute myelogenous leukaemia (AML). Folate receptor (FR) …

Targeted drug delivery has the potential to improve the efficacy of a therapeutic agent while
reducing its side effects. The folate receptor type β (FR-β) is a cell surface marker selectively …

Chemotherapy for AML is hampered by severe side-effects and failure to eliminate all the
blasts that eventually leads to relapse. The use of nanosized particulate drug carriers such …

Fludarabine, a nucleoside analogue antimetabolite, has complicated pharmacokinetics
requiring facilitated transmembrane transport and intracellular conversion to triphosphate …

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the
accumulation of immature myeloid progenitor cells in the bone marrow, compromising of …

Treatment options are limited for patients that are refractory to or relapse after standard
induction chemotherapy for acute lymphoblastic (ALL) or myeloid leukemia (AML). Complete …

Thirteen consecutive adult patients with primary refractory (n= 5) or relapsed (n= 8) acute
lymphoblastic leukemia (ALL) were treated by an induction schedule (FLAG) consisting of …